First patient dosed in Phase I trial of prostate cancer drug
The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC). ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More
